PRECLINICAL - VERY DISAPPOINTING.today announced the Company and its’ collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology’s (“ASN”) Kidney Week 2019 taking place from November 5-10, 2019 in Washington, DC.
I am tired of being a rat on wheel forever chasing my taili. This announcement is not what I am interested in. I want to hear about why the late stage PIII Ryplazim, is waiting forever to happen and why the late phase IVIG was cancelled, and what is happening with other protein development with this mature technology. Also what is happening with the clinical stage 4050 trials etc that we had been waiting to advance for years. So, "PRECLINICAL" POSTERS do not excite me in the least!! We will soon be back to mouse models again. LMNL movement seems to be backward in time, and not advancing their late stage assets at all! I am totally fatigued and very dis[appointed and wondering WHY is this happening?? It's like SALP is wnating to say that the LMNL technology is not worth Billions as it is really still in the "PRECLINICAL" STAGE.. tHEY ARE STILL TRYING TO JUSTIFY THE HARDSHIP CASE!
There won't be any positive market reaction to this PR and this direction in general.